1987
Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation.
Roberts JD, Stewart JA, McCormack JJ, Krakoff IR, Culham CA, Hartshorn JN, Newman RA, Haugh LD, Young JA. Phase I trial of tiazofurin administered by i.v. bolus daily for 5 days, with pharmacokinetic evaluation. Journal Of The National Cancer Institute 1987, 71: 141-9. PMID: 3802111.Peer-Reviewed Original ResearchConceptsTreatment interruptionTransient toxic effectsM2/dayTreatment coursePhase I clinical trialToxic effectsAntitumor activityPhase II trialPhase I trialBolus IV infusionFrequent treatment interruptionsSerum biochemical abnormalitiesSystemic toxic effectsCoadministration of allopurinolMurine tumor modelsUric acid productionLow dose levelsSignificant antitumor activityBolus dailyInjury manifestTransient pericarditisII trialSerum hemoglobinI trialIV infusion
1986
Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro
Roberts J, Tong W, Hartshorn J, Hacker M. Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro. Cancer Letters 1986, 32: 193-197. PMID: 3756845, DOI: 10.1016/0304-3835(86)90119-9.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCells, CulturedErythrocytesHumansLeukocytesPhosphorylationRibavirinRibonucleosides